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colonization by speciﬁc pathogens. It contains polycarbophil, a bioadhesive agent, and lauryl glucoside
(LG), a nonionic surfactant that reinforces the barrier effect through its tensioactive properties.
Objective: To assess the local safety proﬁle, tolerability, and efﬁcacy of Polybactum formulations.
Methods: The following studies were performed on 3 Polybactum formulations: 2 ovules (Type 1: LG
0.04% and Type 2: LG 0.1%) and 1 gel formulation. Bacteriologic tests assessing the effects on normal
vaginal ﬂora and pathogens; in vitro and in vivo tests designed to assess cytotoxicity, as well as irritant
and sensitizing potentials; biocompatibility, barrier, residence time, and absorption tests using recon-
stituted human vaginal epithelium were performed.
Results: Polybactum is a selective bacteriostatic agent that is active against Streptococcus agalactiae and
Gardnerella vaginalis while sparing normal vaginal ﬂora; that is, Lactobacillus spp. It had no cytotoxic,
irritant, and sensitizing effects nor did it impair barrier and fence functions of the vaginal epithelium. The
Type 1 ovule showed ﬁlm-forming properties in vitro. Finally, LG absorption through reconstituted
human vaginal epithelium was negligible, ruling out the risk for possible systemic toxicity.
Conclusions: This favorable preclinical proﬁle is encouraging and supports clinical studies on Polybactum
Type 1 ovules for the prevention and management of recurring bacterial vaginosis.
& 2016. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
One of the most important discoveries in medicine during the
past decade has been the diversity and extent of the human
microbiome. The human body is now perceived as a superorgan-
ism in which a multitude of microbial genomes continually
interact with the human genome. A growing body of evidence
indicates that alterations of the microbiome are associated with a
number of diseases.1
The vaginal microﬂora mainly consists of lactobacilli, which
dominate over pathogenic anaerobes, contributing to vaginal
health. Alterations in the vaginal microﬂora, called bacterial
vaginosis, are very common, occurring in 20% to 50% of fertile,
premenopausal, and pregnant women.2 Bacterial vaginosis isInc. This is an open access article u
Pharm, Efﬁk Italia S.p.A., Via
olino).associated with adverse pregnancy outcomes (ie, prematurity),
increased risk of postpartum infections such as endometritis, and
increased infectious complications after gynecologic procedures,
as well as pelvic inﬂammatory disease. It is also a risk factor for
urinary tract infections and for the acquisition of sexually trans-
mitted diseases, and can directly affect fertility.2–7 Standard
therapy involves oral or local administration of metronidazole or
intravaginal clindamycin. Although short-term success rates may
be as high as 85%, medium- to long-term cure rates are low: the
recurrence rate is up to 35% at 1 month, 50% at 3 months, and 70%
at 12 months.8
Polybactum (Efﬁk International, Brussels, Belgium) is a vaginal
mucoadhesive product designed to form a ﬁlm; that is, a mechan-
ical barrier against colonization by speciﬁc pathogens. It can
therefore contribute to preventing and managing bacterial vagi-
nosis, notably the prevention of relapses. In such cases, it is used
after speciﬁc pharmacologic treatment 3 times in the ﬁrst week.
Its administration is to be repeated for 2 consecutive menstrual
cycles, mainly after menstruation, whereas nonmenstruatingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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3 consecutive months. The ﬁrst administration should always be
immediately preceded by the speciﬁc pharmacologic treatment. It
may also be useful in the prevention of vaginal colonization by
Group B Streptococcus (GBS), also called Streptococcus agalactiae,
which affects 5% to 35% of pregnant women and is associated with
a 50% risk of transmission to newborns.9–13 Newborns infected
with GBS can potentially develop fatal conditions, such as pneu-
monia and sepsis and, more rarely, meningitis.14–17 GBS may also
be responsible for perinatal infections in mothers, such as
endometritis.18
Three Polybactum formulations have been developed (2 different
ovules and a hydro-gel) using 2 main components: polycarbophil, a
polymer with excellent bioadhesive properties19 widely used in
products for buccal, ophthalmic, nasal, vaginal, and rectal applica-
tions, and lauryl glucoside (LG), a nonionic surfactant.20 The tensioac-
tive properties of LG may reinforce the barrier effect of the
formulation by reducing surface tension, thereby contributing to the
mechanical detachment of vaginal pathogens and inhibiting coloni-
zation. In addition, the gel contains carbopol for its gel-forming
properties, and other inert constituents, whereas the ovules contain
Witepsol W35 (Witepsol, Cremer Oleo GmbH & CO. KG, Hamburg,
Germany), a hard fat vehicle used to make ovules.
LG belongs to the alkyl (poly)glycoside molecule family con-
sisting of a hydrophobic alkyl residue derived from a fatty alcohol
and a hydrophilic saccharide structure derived from dextrose,
which are linked through a glycoside bond. Speciﬁcally, the alkyl
substituents range from 2 to 22 carbons in length, and the D-
glycopiranosides consist of glucose-type mono-, di-, tri-, oligo-, or
polysaccharides. Regardless of the degree of polymerization, these
ingredients are simply called glucosides.21
Lauryl (poly)glucoside, International Nomenclature of Cosmetic
Ingredients name (European Union Inventory of Cosmetic Ingredients
(EU) and Cosmetic Toiletry and Fragrance Association (CTFA)) lauryl
glucoside, is listed in the Cosmetic Ingredient Database of the European
Union and in the US Food and Drug Administration Voluntary Cosmetic
Registration Program. LG, as part of the family of alkyl (poly)glycosides
C6-C16, was established to be amongst the compounds generally
regarded as safe (notiﬁcation no. 000237) in 2007. Alkyl glycosides
are not included in Annex 1 of the list of dangerous substances of
Council Directive 67/548/EEC.
Alkyl (poly)glucosides with chains of various lengths have been
investigated in depth to exclude any potential health risks22–24
within occupational and personal care use. Although these studies
are available, the very ﬁrst issue to be addressed in the develop-
ment of a novel product for vaginal administration is biocompat-
ibility and irritation potential with regard to the site of use/
application. For this reason, a series of in vivo and in vitro studies
were conducted to rule out topical hypersensitivity /cytotoxicity of
Polybactum, to assess its inﬂuence on vaginal ﬂora, to establish its
residence time in the vaginal cavity, as well as to quantify any
transepithelial absorption that could be associated with systemic
toxicity. In this article, we report the ﬁndings of the safety proﬁle
studies conducted on 2 Polybactum ovule formulations and 1 gel
formulation, focusing on intravaginal use.Materials and Methods
All biocompatibility studies were carried out according to
International Organization for Standardization in Pharmaceuticals
(ISO) guideline Nos. 10993-5: 2009, 10993-10: 2002, and 10993-
12: 2007. The ISO 10993 set entails a series of standards for
evaluating the biocompatibility of medical devices.
According to rule 5 of the Annex IX of Directive 93/42/EEC, as
amended by Directive 2007/47/EEC, Polybactum is an invasivemedical device because it is introduced into a natural oriﬁce of the
human body (ie, the vagina). Moreover, it is intended to stay on the
vaginal mucosa for more than 60 minutes, but fewer than 30 days.
For this reason, it is classiﬁed as a IIa medical device.
Annex A of ISO 10993-1 establishes that the biological evalua-
tion of a medical device with these characteristics requires testing
of cytotoxicity (ISO 10993-5), irritation (vaginal, ISO 10993-10),
and sensitization (ISO 10993-10).
Three formulations of Polybactum were tested: Type 1 ovule: Polycarbophil 1.50% w/w, LG 0.04% w/w, and C12-
18 acid triglyceride 98.46%; Type 2 ovule: Polycarbophil 1.50% w/w, LG 0.1% w/w, hydro-
genated coco-glycerides 87.4%, glycerol 5.0%, guar gum 5.0%,
and silica 1.0%; and Gel: Polycarbophil 1.50% w/w, carbomer 0.5% w/w, LG 0.04%
w/w, and glycerin 15%, buffered at pH 3.5 to 4.5.
Effects on vaginal ﬂora
Polybactum ovules and gel (25% w/v and 50% w/v ratio,
respectively) were put in direct contact with bacterial suspensions
(41  105 CFU/mL) for 48 hours. The bacterial suspensions tested
were: Lactobacillus crispatus, Lactobacillus jensenii, Lactobacillus
gasseri, Streptococcus agalactiae, Neisseria gonorrhoeae, and Gard-
nerella vaginalis. Additional tests were conducted to determine the
MIC of Polybactum Type 1 and 2 ovules and gel. The product was
diluted (10%, 25%, or 50% w/v) and put in contact with micro-
biological suspensions (41  105 CFU/mL) of S agalactiae, L
crispatus, and G vaginalis for 24 hours, 48 hours, and 72 hours.
pH-dependent efﬁcacy
We prepared 5 aqueous solutions of melted ovules at different
pHs: pH 3, pH 5, pH 7, pH 9, and pH 11. One melted Type 1 or Type
2 ovule was added to 50 mL solution and the induced change in pH
was measured by SevenMulti (Mettler Toledo (Mettler Toledo,
NextPharma, Limay, France)) pH meter equipped with an InLab
Routine Pro (Mettler Toledo, NextPharma, Limay, France) electrode.
Cytotoxicity assay
Cytotoxicity was assessed in Balb 3T3 murine ﬁbroblast cell
line. Brieﬂy, cells were exposed to Type 1 and 2 ovules of
Polybactum in Dulbecco’s modiﬁcation of Eagle’s medium, accord-
ing to the ISO 10993-5 guideline. After 24 hours, cells were
observed under an inverted microscope and cytotoxicity was
evaluated by neutral red uptake.
Cell degeneration and malformations were evaluated after 24
hours’ incubation on a scale ranging from 0 ¼ no degenerated or
malformed cells to 4 ¼ area of degenerated/malformed cells
exceeding the specimen more than 1.0 cm). The acceptability
criteria for the qualitative evaluation were as follows: negative
control r1 and positive control Z3. The negative control was
ﬁlter paper placed in the middle of each well, whereas the positive
control was 30 mm2 latex placed in the middle of each well. For
the quantitative evaluation, the standard deviation of each group
had to be o18% and positive control percentage cellular vitality
had to be o70%. Cytotoxicity was deﬁned as the achievement of a
numerical grade 42 and cellular vitality reduction by 430%.
Vaginal irritation
The tests were performed in compliance with ISO 10993-10.
This test was performed in 6 female white New Zealand rabbits (3
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the ISO guidelines. All animal experiments were performed in
accordance with animal study regulations, and with the approval
of the Animal Care and Use Committee. Both Type 1 ovules and
Type 2 ovules were tested. The test item (1 ovule) was handled to
obtain a bolus of 0.5 g and was introduced with a soft catheter into
the vagina of each animal for 5 consecutive days. Control animals
were treated with a saline solution (0.9% sodium chloride) injec-
tion only under the same conditions. Twenty-four hours after the
initial application and immediately before each test, the vaginal
opening and perineum of each animal were inspected for signs of
discharge, erythema, and edema, and results were recorded,
grading the outcome from 0 to 4.
Twenty-four hours after the last application, rabbits were killed and
subjected to a macroscopic and microscopic examination. Histologic
evaluation was performed on samples collected from 3 areas of each
vagina in proximal-distal direction. The vaginal tissue of each animal
was graded 0 to 4 for each of the following items: epithelium (0 ¼
normal up to 4 ¼ generalized erosion); leukocyte inﬁltration (for high
power ﬁeld 0 ¼ absent 4 ¼ more than 100); vascular congestion (0 ¼
absent up to 4 ¼ marked, with disruption of vessels); and edema (0 ¼
absent up to 4 ¼ marked). Hence, the total score ranged from 0 to 16.
The total scores were added and divided by the number of animals to
obtain an average irritation score. The same calculation was performed
for the control group. A total score 49 for the microscopic evaluation
in the control tissue could suggest an underlying pathology or, in a
control animal, could suggest trauma at dosing. Either situation could
require a retest if the other test or control animals exhibited equivalent
high scores. The control group average was subtracted from the test
group average to obtain the vaginal irritation index.Sensitization potential
The test was performed in 15 þ 3 female albino Guinea pigs
according to ISO 10993-10. Both Type 1 ovules and Type 2 ovules
were tested. To select the sample dilution, 3 occlusive patches with
0.5 mL undiluted and diluted samples (75% and 50% in sodium
chloride) were applied to the back of 3 animals and the dressing
was left in place for 24 hours. After bandage removal, no erythema
was observed at any of the treated sites.
The experimental design included 1 group of 10 treated animals
(Group 1) and one group of 5 control animals (Group 2). The test
consisted of an induction phase and a challenge phase according to the
relevant guideline. Compounds were classiﬁed as positive when at
challenge 30% of animals showed a positive reaction (erythema).Residence time in the vaginal cavity
Residence time was established in young, healthy, female Sprague-
Dawley rats weighing 220 to 250 g. A single dose of the test
formulation (LG 0.04% or LG 0.1% ovule melted by heating up to body
temperature; that is, 371C, or gel) was administered intravaginally
using a cannula in a total volume of 150 mL (volume in excess to ensure
even coating of the entire vaginal mucosal surface area). A total of 150
rats were tested, 50 for each formulation. Five animals were assigned to
each time point for vaginal sampling, so that each rat underwent only
1 vaginal lavage: þ1 hour, þ2 hours, þ4 hours, þ6 hours, þ8 hours,
þ10 hours, þ12 hours, þ24 hours, þ48 hours, and þ72 hours. The
samples obtained from each lavage were placed on a glass slide and
immediately ﬁxed and stained with Alcian blue. Each smear was used
to determine the percentage of cells showing polymer gel adhering to
their surface as well as the absolute number of cells in each sample,
and to perform a semiquantitative analysis of the intensity (density) of
global stain expressed as a score between 0 and 10.Film-forming properties and interaction with vaginal epithelium
barrier function
A study using a commercially available model of reconstituted
human vaginal epithelium (SkinEthic (SkinEthic, Lyon, France)
reconstituted human vaginal epithelium [RHV]) was conducted to
assess the ﬁlm properties and vaginal barrier function of Type 1 and
Type 2 ovules. Formulations devoid of LG were used as placebo
control (1 for each formulation), saline solution as a negative control,
and sodium dodecyl sulfate 1% (SDS 1%) (Sigma-Aldrich, St Louis,
Missouri) as a positive control.
The model reproduces vaginal epithelium morphology; it is
made of an epithelium formed after 5 days of air-lift culture of an
immortalized cell line (A431) in a chemically deﬁned medium. The
tissue and media were manufactured in compliance with ISO 9001.
Experiments were performed following the supplier’s instructions.
Inﬂuence on barrier function and fence properties measured by
transepithelial electrical resistance
The inﬂuence on barrier function and fence properties by trans-
epithelial electrical resistance (TEER) was measured after 6 hours and
24 hours of treatment with Type 1 ovules and before and after 24 to
48 hours of treatment with Type 2 ovules. Measurement time was set
up based on the characteristics of the formulation, with the aim of
differentiating the 2 compositions. Thirty milligrams of each formula-
tion was applied topically on RHV premoisturized with 30 μL saline
solution 1 hour before application, to enable better contact with the
epithelial surface. Thirty microliters of positive control (SDS 1%) and
negative control were applied in the same conditions. TEER was
measured directly on RHV surface before and at the end of treatment,
after removal of each product using Millicell-ERS (range, 0–20 kΩ).
Measurements were repeated 3 times for each tissue. The
t ¼ 0 measurement was set as the baseline and reference value for
each single tissue. The blank value (insert without tissue) was
subtracted from the sample value (mean of 3 measurements). This
result was then corrected considering the tissue surface (0.5 cm2):
4ðmean 3measurementsÞ sample 4blank ¼ 4
 tissue surface ð0:5 cm2Þ:
Barrier permeability measured by Lucifer yellow paracellular passage
An amount of 0.5 mL Lucifer yellow (LY) 500 M in saline was
introduced into the apical compartment of the insert after exposure to
the substance to be tested for the same periods as those listed for TEER.
Then, 1 mL saline solution was added to the basolateral compartment.
The transport of LY was assessed as a switch from apical to basolateral
compartment after an incubation period of 30 minutes at 371C. Values
were read by using a spectroﬂuorimeter (Tecan Inﬁnite M200 (Tecan
Inﬁnite, Vitroscreen, Milan, Italy)) with 428 nm excitation and 535 nm
emission. Fluorescence was measured at apical and basolateral level
and ﬂux was calculated with the following formula:
LY Flux% ¼ ðRFU BL=RFU AP t ¼ 0Þ  100,
where RFU ¼ ﬂuorescence, bl ¼ basolateral, and ap ¼ apical.
Histomorphologic analysis
Histomorphologic analysis was performed after hematoxylin
and eosin (H&E) staining at the end of treatment. Tissue samples
were rinsed with saline solution and ﬁxed in buffered 10%
formalin. Samples were included in parafﬁn blocks and sections
of 5 mm were obtained. Slides were stained with H&E and
evaluated under light microscopy (20 ).
Transepithelial passage
The amount of active LG in the vaginal Type 1 and Type 2 ovule
prototypes was monitored to assess penetration under exposure
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control caffeine 1% (Sigma-Aldrich), and Type 1 ovule placebo
were applied topically onto the epithelium surface. The same
procedure used for the ﬁlm-forming properties assessment was
followed for the application of 500 (5) mg vaginal ovules over a
24-hour period. The selected receptor ﬂuid was bidistilled water
1 mL/well. A quantity of 1000 μL receptor ﬂuid was collected in
plastic tubes at 6 hours and 24 hours and stored at 41C before
being delivered to the analytical laboratories (BioSphere S (Bio-
sphere S, Perugia, Italy) and AR2i (AR2i, Le Plessis Robinson,
France)) for LG level determination by mean of a validated gas
chromatography–mass spectrometry assay. The assay showed that
all validation parameters were satisfactory according to their
generally accepted speciﬁcations for the concentration range
between 0.0004 and 0.01 mg/mL according to International
Council for Harmonisation of Technical Requirements for Pharma-
ceuticals for Human Use standards.24 The total amount of active LG
that penetrated through the epithelium in 24 hours was the sum
of the receptor ﬂuids collected at 6 hours and 24 hours.
Statistical analysis
All in vitro experiments were repeated twice, with representative
results shown. Statistical analysis was calculated by using Microsoft
Ofﬁce Excel (Redmond, Washington). An unpaired Student t test was
used. Differences were considered signiﬁcant at P r 0.05.Results and Discussion
Effects on vaginal ﬂora and pH
The ﬁrst tests were designed to ensure that Polybactum
formulations do not affect the normal vaginal ﬂora and pH, which
are important to prevent colonization of the vagina by pathogens,
such as G vaginalis and S agalactiae. Colonization prevention occurs
through a number of mechanisms, above all by competition with
other microorganisms for nutrients and for adherence to the
vaginal epithelium. Additional mechanisms are stimulation of
the immune system; reduction in vaginal pH via the productionTable I
Inhibiting activity of Type 1 and Type 2 lauryl glucoside ovules.
Strains Initial inoculation
(CFU/mL)
Contact
time (h)
Positive
control
Type 2 formulatio
10% w/v 25% w
Candida albicans (ATCC
10231)
1.6  105 24 1.6  107 43  106 4 3
48 1.6  107 43  106 43 
72 1.6  107 43  106 43 
Streptococcus
agalactiae
(CIP 107.227)
2.6  105 24 2.4  107 o100 o100
48 1.5  107 o100 o100
72 5.5  107 o100 o100
Neisseria gonorrhoeae
(CIP 79.18)
2.0  105
(1.2  105)
24 2.9  108 43  106 1.3 
48 1.4  108 43  106 3.8 
72 43  108 43  106 5.5 
Lactobacillus crispatus
(CIP 103.603)
1.6  105 24 43  108 43  106 1.2 
48 43  108 43  106 1.5 
72 43  108 43  106 43 
Gardnerella vaginalis
(CIP 70.74)
2.1  105 24 1.1  106 4  102 o100
48 1.6  107 2.1  104 o100
72 2.9  107 o100 o100of organic acids, mainly lactic acid; and production of antimicro-
bial substances, such as bacteriocins and hydrogen peroxide.3,26
The vagina is colonized by a number of microorganisms that
interact with each other, forming an ecologic niche. The bacterial
population varies according to age, menstrual status, pregnancy,
sexual activity, medication, and contraceptive use, as well as
hygiene.20,27
Although the growth of pathogens was affected by Polybactum,
the growth of Lactobacillus strains was not (all formed 4106 CFU/
mL) (Table I). G vaginalis was reduced to no more than 102 CFU/mL
(Table I) and S agalactiae to no more than 100 CFU/mL, whereas N
gonorrhoeae was reduced to a lesser degree (7-1-8.3 104 CFU/mL)
(Table II). The test used was able to detect only bacteriostatic and
pseudobactericidal effects, so the results cannot be interpreted as a
documentation of bactericidal effects Table III and IV.
The MICs determined for Type 1 and Type 2 ovules of Polybactum
were as follows: both G vaginalis and S agalactiae o10% and L crispatus
50% (Table I). The MICs determined for the gel were higher: G vaginalis
and S agalactiae 25%, and L crispatus 450% (Table II). Thereafter, the
effect of the gel was not pursued any further.
The next test was designed to verify that Polybactum does not
interfere with the maintenance of an acidic environment. The
addition of a single Type 1 or Type 2 ovule of Polybactum to
solutions maintained at different pHs showed that Polybactum did
not increase pH, if anything it actually reduced it slightly. Con-
sequently, the natural acidifying effect of lactobacilli should not be
affected by Polybactum (Figure 1).Biocompatibility
Alkyl (poly)glycosides with C8-C16 alkyl chains belong to the
group of very mild surfactants for body cleansing formulations. In
a detailed study, the compatibility of alkyl (poly)glycosides was
described as a function of pure C chain. In the modiﬁed During
chamber test, C12 alkyl polyglucoside was the most irritant
compound, albeit within the range of mild irritation effects; C8,
C10, C14, and C16 alkyl polyglucosides produced lower irritation
scores. This is consistent with the ﬁndings related to other classes
of surfactants.27Number of surviving cells (CFU/mL) Minimal inhibitory
concentration (% w/v)
n Type 1 formulation Type 2
formulation
Type 1
formulation
/v 50% w/v 10% w/v 25% w/v 50% w/v
 106 43  106 43  106 43  106 43  106 450 450
106 43  106 43  106 43  106 43  106 450 450
106 43  106 43  106 43  106 43  106 450 450
o100 o100 o100 o100 r10 r10
o100 o100 o100 o100 r10 r10
o100 o100 o100 o100 r10 r10
104 2.4  103 1.3  106
(1.1  10)
6.2  105
(3.8  105)
2.6  104
(2.0  105)
25 50 close to
25
105 8.1  103 3.7  105
(43  106)
6.4  105
(3.5  105)
o100
(9  104)
50 close to
25
50 close to
25
105 1.5  104 6.9  105
(43  106)
6.2  105
(5.6  105)
2.8  105
(5.0  104)
50 close to
25 %
50 close to
25
106 5  104 43  106 1.1  106 5  105 50 450 close
to 50
106 1.1  10 5 1  105 43  10 6 5  104 50 50
106 43  106 2.6  106 9.4  105 1.4  104 450 50
o100 o100 o100 o100 r10 r10
o100 o100 o100 o100 r10 r10
o100 o100 o100 o100 r10 r10
Table II
Inhibiting activity of lauryl glucoside gel.
Strain Initial inoculation
(CFU/mL)
Contact
time (h)
Positive control No. of surviving cells (CFU/mL) MIC (% w/v)
10% (w/v) 25% (w/v) 50% (w/v)
Candida albicans (ATCC 10231) 2.6  105 24 0.9  107 1.9  106 1.0  106 1.9  105 50
48 1.2  107 43  106 1.8  106 1.1  106 450
72 1.8  107 43  106 43  106 2.0  106 450
Streptococcus agalactiae (CIP 107.227) 0.7  105 24 3.8  107 7.2 105 o100 o100 25 close to 10
48 2.5  107 43  106 o100 o100 25
72 4.6  107 43  106 o100 o100 25
Neisseria gonorrhoeae (CIP 79.18) 1.2  105 24 1.1  106 43  106 4.4  105 o100 50 close to 25
48 8.9  107 43  106 4.5  105 o100 50 close to 25
72 1.3  106 43  106 8.0  105 o100 50
Lactobacillus crispatus (CIP 103.603) 1.2  105 24 1.1  108 2.4  106 1.9  106 1.3  106 450
48 2.6  108 43  106 43  106 43  106 450
72 43  106 43  106 43  106 43  106 450
Gardnerella vaginalis (CIP 70.74) 1.1  105 24 1.3  106 1.0  105 o100 o 100 r10
48 1.7  106 1.4  105 o100 o 100 E10
72 1.7  106 2.3  105 o100 o 100 25 close to 10
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membrane of fertilized hens’ eggs as an alternative to Draize’s
mucous membrane compatibility test, shows a monotonic decrease
from C8 to C14 alkyl polyglucosides within the range of mild
irritation effects. The commercial alkyl polyglycoside products
(Plantacare 1200, Plantacare 2000, and Plantacare 818 (Plantacare,
BASF, Levallois, France)) with mixed carbon chain length have the
best overall compatibility with the relatively high proportion of
long-chain alkyl polyglucosides.27
Regarding clinical studies, the sensitization potential of 0.5%,
0.75%, and 1.8% active ingredient decyl glucoside (in formulation), 5%
active ingredient aqueous decyl and LG, and 1% active ingredient
aqueous coco-glucoside was evaluated in a human repeated insult
patch test.21 The ingredients were not irritating or sensitizing.
Because LG is not considered to be a skin irritant or a mucous
membrane irritant and sensitizer, and being included in the
Polybactum formulation (0.04%) at a very low concentration, we
did not expect any speciﬁc issue from a biocompatibility point
of view.
The next step was to conﬁrm biocompatibility by verifying the
absence of cytotoxic, irritant, and sensitizing effects of Polybactum
in vitro and in vivo. The exposure of ﬁbroblasts to Type 1 ovules of
Polybactum disclosed a negligible reduction in vitality, accounting
for no more than 2.37%; the exposure to Type 2 ovules disclosed a
slightly higher reduction in vitality, which was still small enough
to determine that the formulation was not cytotoxic (–9.22%).Table III
MICs found for vaginal ovules.
Strain Contact time (h) MIC (% w/v)
Type 2 ovule Type 1 ovule
Candida albicans 24 450 450
48 450 450
72 450 450
Streptococcus agalactiae 24 r10 r10
48 r10 r10
72 10 r10
Neisseria gonorrhoeae 24 25 50 close to 25
48 50 close to 25 50 close to 25
72 50 close to 25 50 close to 25
Lactobacillus crispatus 24 50 450 close to 50
48 50 50
72 450 50
Gardnerella vaginalis 24 r10 r10
48 r10 r10
72 r10 r10Regarding vaginal irritation, the results are detailed in Figure 2.
There were no macroscopic ﬁndings. According to microscopic
ﬁndings (not shown), the mean irritation capacity of Type 1 ovules
was 3.67 versus 2.67 related to sodium chloride, whereas the
mean irritation capacity of Type 2 ovules was similar to that of
sodium chloride. Whereas Type 1 ovules were reported to be
minimally irritating, Type 2 ovules were found not to be irritating
at all. The lack of dose response with regard to LG suggested that
minimal irritation with Type 1 ovules may have been a chance
ﬁnding, rather than the expression of an irritation potential that
would increase with additional use.
Moreover, none of the animals exposed to the Type 1 or Type
2 ovules of Polybactum exhibited signs of sensitization. Thus, we
concluded that Polybactum ovules were not cytotoxic or irritating,
nor did they induce sensitization, thus conﬁrming the original
hypothesis.
Residence time in the vaginal cavity
Residence time of the 0.04% ovule in the vaginal cavity was very
satisfactory: the mean (SD) percentage of cells that still had
polymer adhering to them at 48 hours was 99% (2.1%) and at 72
hours 91% (8.1%); mean (SD) staining was still intense, at 7.4 (1.5)
and 7.4 (1.3), respectively (Figure 3). Residence time of the 0.1%
ovule in the vaginal cavity was similar: The mean (SD) percentage
of cells that still had polymer adhering to them at 48 hours was
95% (6%) and at 72 hours 93.4% (9.8%). Mean (SD) staining was
not quite so intense, at 6.4 (1.1) and 7.2 (1.1), respectively.Table IV
MICs found for vaginal gel.
Strain Contact time (h) MIC (% w/v)
Candida albicans 24 50
48 450
72 450
Streptococcus agalactiae 24 25 close to 10
48 25
72 25
Neisseria gonorrhoeae 24 50 close to 25
48 50 close to 25
72 50
Lactobacillus crispatus 24 450
48 450
72 450
Gardnerella vaginalis 24 r10
48 E10
72 25 close to 10
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Fig. 1. Changes in pH induced by the introduction of a single Type 1 or Type 2 Polybactum (Efﬁk International, Brussels, Belgium) ovule into 50 mL solutions at different pHs.
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residence time of the ovules: The mean (SD) percentage of cells
that still had polymer adhering to them at 48 hours was 87.2%
(18.1%) and at 72 hours 88.2% (5.0%). However, mean (SD) staining
was still intense, at 7.4 (2.4) and 7.8 (1.4), respectively.
In vitro effects on vaginal barrier and ﬁlm-forming properties
Caprylyl glucoside increases the absorption of poorly absorbed
drugs (eg, insulin) both in vitro across human carcinoma mono-
layers and in vivo through mucosal membranes. The effect of other
alkyl glycosides, including decyl glucoside and LG, on mucosal
penetration was also evaluated. A 5% solution of decyl glucoside
also enhanced the buccal absorption of insulin, whereas 5% LG did
not have the same effect. Researchers have stated that there is no
consistent relationship between alkyl chain length and penetra-
tion enhancement.28
To conﬁrm that LG does not affect vaginal mucosa barrier and
fence properties, TEER measurements were used. TEER is the
measure of the movement of ions across the paracellular pathway
regulated by polarized plasma membrane surfaces and by cell-to-
cell tight junctions, which, together, prevent movement of solutes
and ions across the epithelium. TEER is an indirect assessment of
tight junction stability and, consequently, is a direct measure of
barrier function in epithelial tissue because it reﬂects the global
resistance of the barrier linked both to the structure and to
epithelial thickness. Maintenance of stability and electrical resist-
ance of an epithelium is critical for essential physiological proc-
esses. Therefore, signiﬁcant changes in TEER may be an early3,67
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Fig. 2. Severity of macroscopic and microscopic ﬁndings, and vaginal irritation index ex
2 Polybactum (Efﬁk International, Brussels, Belgium) ovules introduced daily for 5 days
3 control animals.expression of cell damage and can be considered as a comple-
mentary parameter.
TEER was directly measured on RHV surfaces before and at the
end of treatment after product removal.
Figure 4 shows that none of the Polybactum formulations
inﬂuenced epithelial fence properties. Moreover, their effects were
considerably lower than the effects of the positive control, which
ranged between –58% and –67%. The effects of Type 2 Polybactum
ovules were considerably lower, ranging between –16% and –44%
and Type 1 Polybactum ovules actually increased resistance by 78%
after 24 hours (P o 0.01 vs placebo), thus exhibiting good ﬁlm-
forming properties.
Due to the superiority of the ﬁlm-forming properties exhibited
by Type 1 ovules, further studies on the effects on vaginal
epithelium were performed only with this formulation.
Barrier integrity was assessed in-depth by means of the LY
assay. LY is a ﬂuorescent dye impermeable to the cell membrane,
which is used to study the paracellular permeability of a sub-
stance. When the junctions are unbroken,
LY has a very low permeability; if the joints are damaged, LY ﬂow
will be much higher. Therefore, this assay is used to verify the
integrity of cell junctions in the presence of the substance to be
evaluated. The results obtained with this dye showed that only the
SDS 1% increased permeability, increasing LY assay 2-fold (Figure 5).
The ultimate conﬁrmation that Polybactum did not have any
untoward effects on vaginal epithelium was provided by the
histomorphologic evaluation based on H&E staining. Only SDS 1%
produced loss in cell-to-cell connections and structural modiﬁca-
tions in the whole tissue at 6 hours. Only slight changes were2,67 2,67
0 0
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macro exam
micro exam
vaginal irritation index
pressed on a 5-item semiquantitative scale after exposure to 0.5 g Type 1 or Type
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Fig. 3. (A) Mean (SD) staining intensity score as an index of ovule density over 72 hours after intravaginal administration. (B) Mean (SD) percentage of cells showing polymer
adhering to their surface over 72 hours after intravaginal administration.
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progressed to intermediate modiﬁcations with reduced connection
among cells both with placebo and Type 1 ovules (Figure 6).
Transepithelial passage
The dermal penetration of caprylyl/capryl glucoside (dilution at
10% in Hanks’ buffered salt solution [pH 6.5]) was evaluated
in vitro by using human skin. The mean absorbed dose of
caprylyl/capryl glucoside, as the sum of the amounts found in
viable epidermis, dermis, and receptor medium, was 0.01%.29
Literature studies show that glucoside hydrolases occur in human
skin, stomach, intestine, and mucosa.30CN SDS 1% TYPE 1 OVULES
6h - 37 - 67 - 1 
24h - 5 - 62 78 
48h - 9 - 58 0 
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Fig. 4. Changes in transepithelial electrical resistance (%) as a measure of inﬂuence on ba
application of negative control (CN), positive control (SDS 1%), Type 1 and Type 2 ovuleThe last issue addressed was the potential for systemic toxicity
due to transvaginal passage of LG, although none was expected.
Type 1 and Type 2 ovules were applied topically onto the
epithelium surface and LG levels were determined in the baso-
lateral compartment after 6 hours and 24 hours, using absorption
of caffeine as a positive control. To avoid analytical interference
and according to previous testing with LG, the selected receptor
ﬂuid was bidistilled water 1 mL/well. Type 1 ovule placebo,
without LG, was tested in parallel to exclude any analytical
interferences of the raw materials with the detection of LG.
Negligible amounts of LG were detected after Type 1 and Type
2 ovule application, whereas large amounts of caffeine were
absorbed (68.9%) (Table V). Thus, we conclude that LG was notPLACEBO TYPE 1 
OVULES
TYPE 2 OVULES
PLACEBO TYPE 2 
OVULES
60 0 0 
- 12 - 16 - 16 
0 - 20 - 10 
0 - 44 - 40 
rrier function and fence properties of vaginal epithelium, in the 72 hours following
s, and relative placebos.
CN = negative control  SDS = positive control
CN SDS TYPE 1 OVULES PLACEBO TYPE 1 OVULES
6h 9,4 15,1 5,1 3,0
24h 7,23 30,46 3,91 15,61
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Fig. 5. Changes in the extent of Lucifer yellow ﬂux (%) as a measure of permeability 6 and 24 hours after exposure to Type 1 Polybactum (Efﬁk International,
Brussels, Belgium) ovule and negative control (CN) and positive control (SDS) formulations.
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Fig. 6. Histomorphologic analysis by haematoxilin and eosin staining after product treatments to conﬁrm the results obtained and for a deeper understanding of
the type of interaction between the product and the living tissue.
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Table V
Absorption rates through reconstituted human vaginal epithelium (RHV).
Product Dose applied Lauryl glucoside %
determined after
penetration/diffusion on
RHV in basolateral
compartment
Quantity applied
(formulation)
(mg/0.5 cm2)
Quantity applied
(Lauryl glucoside)
(mg/0.5 cm2)
6 h 24 h Total
receptor
ﬂuid
Mean (SD)
Type 2 ovule 501 (3) 0.5 0.040 0.055
0.095
Type 1 ovule 504 (1) 0.2 0.098 0.089
0.187
Placebo 496 0.0 0.000 0.000 0.000
Caffeine
1%
502 (2) 5.02* 36.78 32.19 68.97
n Caffeine, not lauryl glucoside.
L.I. Ardolino et al. / Current Therapeutic Research 83 (2016) 13–21 21absorbed through the vaginal epithelium. This excludes the risk of
systemic effects.Conclusions
Polybactum is a vaginal mucoadhesive product designed to form a
ﬁlm that acts as a mechanical barrier against colonization by patho-
gens. This article reports preclinical studies addressing a number of
important safety proﬁle issues. Polybactumwas shown in our study to
have no cytotoxic, irritant, or sensitizing effects. It also did not impair
natural defenses because it did not affect the normal vaginal ﬂora, pH,
and/or epithelium fence properties. Type 1 ovule formulation was also
found to have ﬁlm-forming properties. Lastly, it was noted that
although residence time was good, with approximately 90% of cells
showing adhering polymer 72 hours after administration, permeation
of LG (the only component that is not already used in vaginal
formulations) through RHV was negligible. This ﬁnding rules out the
risk for systemic exposure to a substance with potentially unknown
untoward effects. The safety proﬁle of the other constituents is well
known. This favorable preclinical proﬁle is encouraging and warrants
further studies on Polybactum Type 1 ovules as adjunct therapy for
important vaginal infections, as well as for the prevention of recurring
bacterial vaginosis and S agalactiae colonization.Acknowledgments
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